Arena Pharmaceuticals Культура компании

Mr. Amit D. Munshi has been the Chief Executive Officer and President of Arena Pharmaceuticals, Inc. since May 11, 2016. Mr. Munshi served as an Interim Principal Financial Officer of Arena Pharmaceuticals, Inc. from May 11, 2016 to June 15, 2016. Prior to Arena Pharmaceuticals, he served as the Chief Executive Officer and President of EPIRUS Biopharmaceuticals, Inc. from July 15, 2014 to May 6, 2016. Mr. Munshi served as the President and Chief Executive Officer at Percivia LLC (Sold To Johnson & Johnson) from 2011 to 2012. He co-founded Kythera Biopharmaceuticals, Inc. in 2005 and served as its Chief Business Officer and Advisor from 2005 to 2010. He was an Advisor of Cynvenio Biosystems, Inc. He held leadership positions at Amgen Inc. Globally In Multiple Product Management, General Management and Corporate Development Positions from 1997 to 2005, including General Manager of European Nephrology. He has more than 25 years of pharmaceutical and biotechnology experience, including general management, product development, licensing and business development. Mr. Munshi serves on the boards of Oxeia Biopharmaceuticals, Inc., and Cytrellis Biosystems, Inc., both privately held companies. He has been a Director at Arena Pharmaceuticals, Inc. since June 13, 2016. He has been a Director at Pulmatrix, Inc. since June 2017. He served as a Director at Cynvenio Biosystems, Inc. since August 3, 2011. He served as a Director of EPIRUS Biopharmaceuticals, Inc. since July 15, 2014 until May 6, 2016. Mr. Munshi holds a BA in History and a BS in Economics from the University of California at Riverside and an MBA from the Peter F. Drucker & Masatoshi Ito Graduate School of Management at Claremont Graduate University.

Mr. Kevin R. Lind has been the Chief Financial Officer and Executive Vice President at Arena Pharmaceuticals, Inc. since June 15, 2016. Mr. Lind served as the Principal Accounting Officer at Arena Pharmaceuticals, Inc. since August 10, 2016. He has with over 15 years of experience in healthcare banking and private equity. Mr. Lind is lead underwriter of TOP's Life Sciences structured investments and drug royalty monetizations effort. Mr. Lind was the Vice President at TPG Biotech. Prior to Arena, Mr. Lind was at TPG, as a Principal at TPG Special Situations Partners and initially at TPG-Axon'sPharma Partners group. Mr. Lind was instrumental in the structured and royalty effort at TPG-Axon. Mr. Lind was a Member of the TPG Pharma Partners effort at TPG-Axon from 2006 to 2008. Prior to joining TPG-Axon in 2006, Mr. Lind held over five years of experience in Lehman Brothers' Healthcare Investment Banking group, starting in 1998. where he completed over 20 mergers and acquisitions, partnering agreements and financings for life sciences and medical device companies. Mr. Lind is a Board Observer of Edev S.???.r.l. He was a JDC observer for a structured investment at TPG-Axon. Mr. Lind received an M.B.A. from UCLA Anderson School of Management and a B.S. in Biological Sciences from Stanford University.

Mr. Vincent E. Aurentz, also Known as Vince, has been the Chief Business Officer and Executive Vice President at Arena Pharmaceuticals, Inc. since August 15, 2016. Mr. Aurentz served as the Chief Business Officer and Senior Vice President of EPIRUS Biopharmaceuticals, Inc. since November 10, 2015. Mr. Aurentz served as an Executive Vice President of Customer Solutions Business at Quintiles Transnational Corp. since December 2010, where he created a new business model to engage their customers. He served as President of HemoShear, LLC since June 2015 and also served as its Member of Board of Managers since June 2015. He served as Chief Business Officer of HemoShear, LLC since August 2013 until June 2015. He has more than 27 years of experience in the biopharma industry. He served as Executive Vice President of Portfolio Development and a member of the Executive Board, for Merck Serono in Geneva Switzerland, where he headed R&D Product teams, Portfolio Management, Business Development & Licensing, as well as Pricing & Health Economics. He was responsible for Licensing and Business Development, Global Product leadership for the R&D pipeline and Portfolio Management. Prior to his role at Merck Serono, he served as Merck KGaA's Global Head of Licensing and Business Development. He was employed at Merck KGaA for nine years. Mr. Aurentz was a Co-Founder and Managing Director of True North Partners, a venture capital and advisory business focused on the healthcare industry. He served as a partner for CSC Healthcare in New York and worked at Andersen Consulting (now known as Accenture).

Mr. Steven W. Spector, JD, has been General Counsel, Executive Vice President and secretary at Arena Pharmaceuticals, Inc. since October 2001, February 2012 and November 2001 respectively. Mr. Spector served as Senior Vice President since of Arena Pharmaceuticals, Inc. He served as Vice President of Arena Pharmaceuticals Inc. from October 2001 to June 2004. Prior to joining Arena Pharmaceuticals Inc., Mr. Spector was a partner with the law firm of Morgan, Lewis & Bockius LLP, where he worked from 1991 to October 2001. He served as outside corporate counsel of Arena Pharmaceuticals Inc. from 1998 to October 2001. He served as President of the Association of Corporate Counsel, San Diego. He serves as Director of ChemNavigator. He served as Director of BRL, a subsidiary of Arena Pharmaceuticals, Inc. He was also a member of Morgan Lewis' Technology Steering Committee. Mr. Spector holds B.A. and J.D. degrees from the University of Pennsylvania.

Mr. Craig Michael Audet, Ph.D., served as the Senior Vice President of Operations and Head Global Regulatory Affairs at Arena Pharmaceuticals, Inc. since July 5, 2012 until October 10, 2016. Mr. Audet joined Arena Pharmaceuticals in April 2011 as Vice President of Regulatory Affairs, and has led Arena's interactions with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). He has more than 25 years of industry experience. Prior to joining Arena, he served as Vice President and Head of the US Regulatory Affairs Marketed Products Group at Sanofi-Aventis from 2003 to 2008. Before this, he was the Cardiovascular Global Therapeutic Area Leader at Pfizer. He received a bachelor's degree in biology/pre-medicine from Boston College, and is in the process of obtaining his Ph.D. in Public Health.

Dr. Preston S. Klassen, M.D., M.H.S., has been Chief Medical Officer and Executive Vice President of Research & Development at Arena Pharmaceuticals, Inc. since March 20, 2017. Dr. Klassen served as the Chief Medical Officer of Laboratoris Sanifit, S.L. since June 07, 2016. Dr. Klassen served as an Executive Vice President and Head of Global Development at Orexigen Therapeutics, Inc. from February 2015 to May 23, 2016 and served as its Senior Vice President of Product Development and Head of Global Contrave Program since November 2009. He served as Head of Global Development and Senior Vice President at Orexigen Therapeutics, Inc. Dr. Klassen led the global development program for Contrave. Formerly the Therapeutic Area Head for Nephrology and Executive Medical Director at Amgen, Dr. Klassen led global development efforts for its renal franchise. While at Amgen, Dr. Klassen oversaw Phase 2-4 clinical activity for products addressing renal, diabetes and other metabolic diseases. Dr. Klassen has over 20 years of experience in biopharmaceutical product development. He has nearly 14 years of industry experience. His experience includes global regulatory filings, including NDA and sNDA submissions, development and execution of several large cardiovascular outcomes trials and clinical commercialization activities for marketed products. Starting in 2006, Dr. Klassen played a lead role in regulatory interactions related to the benefit/risk profile of erythropoietin stimulating agents for renal indications, including presenting at a 2007 joint meeting of the FDA Cardiovascular and Renal Drugs and the Drug Safety and Risk Management Advisory Committees. Prior to joining Amgen, Dr. Klassen was a Faculty Member in the Division of Nephrology at Duke University Medical Center from 1997 to 2002. Dr. Klassen has been an Independent Director of Conatus Pharmaceuticals Inc. since February 10, 2014. Dr. Klassen received his M.D. from the University of Nebraska College of Medicine and completed his residency in Internal Medicine, fellowship in Nephrology and M.H.S. degree at Duke University.

Dr. Cheryl Lassen, BSc., MBBCh, has been the Chief Medical Officer and Executive Vice President of Research & Development at Arena Pharmaceuticals, Inc. since May 12, 2017 and served as its Vice President of Clinical Development since June 2016 until May 12, 2017. Dr. Lassen served as Vice President of Clinical Development at EPIRUS Biopharmaceuticals, Inc., until May 11, 2016. Dr. Lassen served as Vice President of Clinical Development at Cytos Biotechnology AG since March 12, 2013 and led the clinical development activities at Cytos. She was responsible for development of an immune modulator for asthma. She served as Program Leader of Novartis (UK) for the Global Clinical Development for a respiratory compound since approved by the US FDA, EMA, Japan, China and many countries worldwide. She has over 25 years of pharmaceutical and biotechnology experience in leadership of global clinical development programs from phase 1 to phase 4, health authority approval (FDA, EMA, Japan, China and ROW) and global commercialization. She has extensive experience in medical affairs, regulatory affairs, drug safety and business development. She also served Medical Director positions for Abbott Laboratories and Pharmacia (South Africa) and has over 20 years Clinical Development, Regulatory Affairs and Medical Affairs experience. Dr. Lassen has MBBCh (equivalent to MD) from the University of the Witwatersrand in South Africa and holds a Science degree in Microbiology and Physiology from the University of South Africa.

Kevin Lind serves as the CFO of Arena Pharmaceuticals, Inc.. Kevin started at Arena Pharmaceuticals, Inc. in June of 2016. Kevin currently resides in San Francisco Bay Area.

Steven Spector serves as the Executive Vice President, General Counsel & Secretary of Arena Pharmaceuticals, Inc.. Steven started at Arena Pharmaceuticals, Inc. in September of 2001. Steven currently resides in Greater San Diego Area.

Lopa Desai serves as the VP, Global Strategic Marketing & Planning of Arena Pharmaceuticals, Inc.. Lopa started at Arena Pharmaceuticals, Inc. in January of 2019. Lopa currently resides in the Greater Los Angeles Area.